Mectizan Expert Committee Statement on Potential Efficacy of Ivermectin on COVID-19 (2020)

Other · Mectizan Expert Committee / Mectizan Donation Program · April 7, 2020

Mectizan Expert Committee / Mectizan Donation Program, 2020-04-07: The donation programme's expert committee statement on the Caly et al. in-vitro paper, cautioning that effective antiviral concentrations exceed approved doses.

the high concentration of ivermectin needed to produce anti-viral effects in laboratory tissue culture is far beyond dosage levels approved by the FDA for treatment of parasites in humans and known to be safe and well tolerated

Mectizan Expert Committee / Mectizan Donation Program, 2020-04-07: The donation programme's expert committee statement on the Caly et al. in-vitro paper, cautioning that effective antiviral concentrations exceed approved doses. C10. Statement published on the MDP homepage, carried in the site's COVID-19 section; no separate date is printed on the statement itself, so 2021 is recorded as the year of the statement's subject matter (the Caly et al. in-vitro report was published 2020) and the page is undated – access date 2026-11-19. Attributed to the Mectizan Expert Committee, not to Merck & Co. directly. Recorded as written.